Abstracts tagged "giant cell arteritis"

Abstract Number: 0483 • ACR Convergence 2022
Giant Cell Arteritis: Physical Examination of the Superficial Temporal Arteries Can Predict Temporal Artery Biopsy Result
Giuseppe Germanò¹, Pierluigi macchioni², Giulia Klinowski¹, Alberto Cavazza³, Luigi Boiardi³ and Carlo Salvarani⁴, ¹Arcispedale IRCCS Santa Maria Nuova, Reggio Emilia, Emilia-Romagna, Italy, ²Arcispedale IRCCS Santa Maria Nuova, Reggio Emilia, Italy, ³Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: The detection of temporal arterial abnormalities (TA) is one of the ACR 1990 criteria to define the diagnosis of cranial Giant Cell Arteritis (GCA).…
Abstract Number: 1147 • ACR Convergence 2022
Transcriptomic Changes Induced by Tocilizumab in Ex-Vivo PBMCs from Patients with GCA in Remission. Predictors of Response
Marco A Alba¹, Roser Alba¹, Georgina Espigol Frigolé², Javier Marco Hernández², Sergio Prieto², Marc Corbera-Bellalta³ and Maria C Cid³, ¹IDIBAPS, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Hospital Clinic, University of Barcelona, Barcelona, Spain
Background/Purpose: Glucocorticoids (GCs) are only effective therapy able to induce disease remission, but most patients relapse when GC are tapered and suffer from GC-related toxicity.…
Abstract Number: 0468 • ACR Convergence 2022
Ultrasound Wall Thickness in the Differential Diagnosis of Atherosclerosis and Large Vessel Giant Cell Arteritis
Eugenio De Miguel¹, Jose Maria Mostaza², Carlos Lahoz², Juan Molina³, Elisa Fernandez-Fernandez¹ and Irene Monjo⁴, ¹Hospital Universitario La Paz, Madrid, Spain, ²Hospital Carlos III, Madrid, Spain, ³Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴Hospital Universitario La Paz - IdiPAZ, Madrid, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in the elderly and large vessel involvement (LV-GCA) occurs in up to 50% of cases.…
Abstract Number: 0484 • ACR Convergence 2022
Epidemiology and Predictors of Relapse in Giant Cell Arteritis: A Systematic Review and Meta-analysis
Lien Moreel¹, Albrecht Betrains¹, Geert Molenberghs², Steven Vanderschueren¹ and Daniel Blockmans¹, ¹University Hospitals Leuven, KU Leuven, Leuven, Belgium, ²KU Leuven, Leuven, Belgium
Background/Purpose: The aim of this study was to estimate the timing of relapse, the prevalence of multiple relapses and the predictors of relapse in patients…
Abstract Number: 1202 • ACR Convergence 2022
Clinical Profile and Trend of Vasculitis in Patients with Acute Coronary Syndrome – Insight from National Database 2010 to 2019
Palak Shah¹, Ana Arevalo², Rasha Alaameri³, Brinda Basida⁴, Urja Nagadia⁵, Sanket Basida⁵, shobhana Chaudhari⁶ and Monil Majmundar⁷, ¹Metropolitan Hospital Center, New York Medical College, New York, NY, ²University of Chicago, Chicago, IL, ³New York Medical College/ Metropolitan Program, New York, NY, ⁴DMC/Sinai Grace Hospital, Detroit, MI, ⁵University of Missouri, Columbia, MO, ⁶NYC Health and Hospital/Metropolitan Hospital, New York, NY, ⁷University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Vasculitides are characterized by inflammation of vessel walls with reactive damage to mural structures leading to compromise of the lumen. Vasculitides also accelerate atherosclerosis…
Abstract Number: 0469 • ACR Convergence 2022
Factors Associated with Corticosteroid Dosing in the Management of Giant Cell Arteritis
Loukas Kakoullis and Shiv Sehra, Mount Auburn Hospital, Cambridge, MA
Background/Purpose: Corticosteroids are the cornerstone of therapy in patients with giant cell arteritis (GCA). Tapering regiments vary considerably in both dose and duration, while relapses…
Abstract Number: 0485 • ACR Convergence 2022
Assessing the Effectiveness of Tocilizumab in Newly Diagnosed Giant Cell Arteritis versus Refractory/recurrent Giant Cell Arteritis in Clinical Practice
Julio Sánchez-Martín¹, Javier Loricera², Clara Moriano³, Santos Castañeda⁴, F. Javier Narváez⁵, Vicente Aldasoro⁶, Olga Maiz⁷, Rafael Melero⁸, Juan Ignacio Villa Blanco⁹, Paloma Vela-Casasempere¹⁰, Susana Romero Yuste¹¹, José Luis Callejas¹², Eugenio De Miguel¹³, Eva Galíndez-Agirregoikoa¹⁴, Francisca Sivera¹⁵, Jesus Fernandez¹⁶, Carles Galisteo¹⁷, Ivan Ferraz Amaro¹⁸, Lara Sánchez-Bilbao¹, Monica Calderon-Goercke¹⁹, Miguel Ángel González-Gay²⁰ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁵Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷Hospital Universitario de Donostia, San Sebastián, Spain, ⁸Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ⁹Sierrallana Hospital, Torrelavega, Spain, ¹⁰Hospital General Universitario Alicante, Alicante, Spain, ¹¹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹²Hospital San Cecilio, Granada, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁶Hospital de La Coruña, La Coruña, Spain, ¹⁷Hospital Parc Tauli,, Sabadel, Spain, ¹⁸Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ¹⁹Hospital de Sierrallana, Torrelavega, Spain, ²⁰Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Tocilizumab (TCZ) is the only biologic drug approved in giant cell arteritis (GCA), based in two clinical trials (CT) (1,2). CT included selected patients…
Abstract Number: 1245 • ACR Convergence 2022
Imaging Use and Medication Management in Giant Cell Arteritis
Aradhna Agarwal¹, Reid Weisberg¹, Jiby Mathew², Andreas Reimold³ and Kyawt Shwin¹, ¹UT Southwestern, Dallas, TX, ²VA North Texas Health Care System/Dallas VA Medical Center, Dallas, TX, ³University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Giant cell arteritis (GCA) affects medium and large arteries. Although temporal artery biopsy (TAB) remains the gold standard for patients with cranial GCA, patients…
Abstract Number: 0470 • ACR Convergence 2022
Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial
Lisa Christ¹, Luca Seitz², Godehard Scholz¹, Lukas Buetikofer³, Florian Kollert¹, Stephan Reichenbach⁴ and Peter Villiger⁵, ¹Department of Rheumatology and Immunology, University of Bern, Inselspital, Bern, Switzerland, ²Department of Rheumatology and Immunology, University of Bern, Inselspital, Switzerland, ³CTU Bern, University of Bern, Bern, Switzerland, ⁴University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland, ⁵Medical Center Monbijou, Rheumatology and Immunology, Bern, Switzerland
Background/Purpose: Two randomised controlled trials (RCT) [1, 2] demonstrated a glucocorticoid (GC)-sparing effect of tocilizumab (TCZ) of at least 50% in the treatment of giant…
Abstract Number: 0486 • ACR Convergence 2022
Gene Expression Profile of Temporal Artery Tissue and Whole Blood in Giant Cell Arteritis
Marcia Friedman¹, Daniel Albert², Dongseok Choi³, Hillary Stiefel², Colin Oglesbee-Venghaus², Kimberly Ogle², Christina Harrington⁴, David Wilson² and James T. Rosenbaum⁵, ¹Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR, ²Casey Eye Institute, Portland, OR, ³OHSU-PSU School of Public Health, Portland, OR, ⁴Oregon Health & Science University, Portland, OR, ⁵Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Diagnosing giant cell arteritis GCA is notoriously challenging, as there are no reliable blood biomarkers and temporal artery biopsy (TAB) has a sensitivity of…
Abstract Number: 1257 • ACR Convergence 2022
Assessing the Effectiveness of Tocilizumab in Giant Cell Arteritis by PET: Multicenter Study of 101 Patients of Clinical Practice
Julio Sánchez-Martín¹, Javier Loricera¹, Santos Castañeda², Clara Moriano³, F. Javier Narváez⁴, Vicente Aldasoro⁵, Olga Maiz⁶, Rafael Melero⁷, Juan Ignacio Villa Blanco⁸, Paloma Vela-Casampere⁹, Susana Romero Yuste¹⁰, José Luis Callejas¹¹, Eugenio De Miguel¹², Eva Galíndez-Agirregoikoa¹³, Francisca Sivera¹⁴, Jesus Fernandez¹⁵, Carles Galisteo¹⁶, Ivan Ferraz Amaro¹⁷, Lara Sánchez-Bilbao¹, Monica Calderon-Goercke¹⁸, Miguel Ángel González-Gay¹⁹ and Ricardo Blanco²⁰, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Hospital Universitario de Navarra, Pamplona, Spain, ⁶Hospital Universitario de Donostia, San Sebastián, Spain, ⁷Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Sierrallana Hospital, Torrelavega, Spain, ⁹Hospital General Universitario Alicante, Alicante, Spain, ¹⁰Complexo Hospitalario Universitario, Pontevedra, Spain, ¹¹Hospital San Cecilio, Granada, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Basurto University Hospital, Bilbao, Spain, ¹⁴Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁵Hospital de La Coruña, La Coruña, Spain, ¹⁶Hospital Parc Tauli,, Sabadel, Spain, ¹⁷Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ¹⁸Hospital de Sierrallana, Torrelavega, Spain, ¹⁹Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ²⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Positron emission tomography (PET) is one of the tools available for the diagnosis of extracranial large-vessel vasculitis (1-5). Tocilizumab (TCZ) has shown efficacy in…
Abstract Number: 0471 • ACR Convergence 2022
Serum Proteomics in Giant Cell Arteritis: Findings of the Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab Trial (The GUSTO Trial)
Lisa Christ¹, Andrea Gloor², Florian Kollert¹, Timo Gaber³, Frank Buttgereit³, Stephan Reichenbach⁴ and Peter Villiger⁵, ¹Department of Rheumatology and Immunology, University of Bern, Inselspital, Bern, Switzerland, ²Department of Internal Medicine, University of Bern, Inselspital, Bern, Switzerland, ³Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, ⁴University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland, ⁵Medical Center Monbijou, Rheumatology and Immunology, Bern, Switzerland
Background/Purpose: Measuring disease activity in patients with giant cell arteritis (GCA) remains challenging since appropriate biomarkers are missing, particularly, if tocilizumab (TCZ) is prescribed which…
Abstract Number: 0487 • ACR Convergence 2022
A Systematic Literature Review to Generate Descriptors for the Development of New Response Criteria in Giant Cell Arteritis
Catalina Sanchez Alvarez¹, Milena Bond², Medha Soowamber³, Dario Camellino⁴, Zahi Touma⁵, Sofia Ramiro⁶, Melanie Anderson⁷, Carol Langford⁸ and Christian Dejaco⁹, ¹University of Florida, Gainesville, FL, ²Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ³Mount Sinai Hospital, Woodbridge, ON, Canada, ⁴Azienda Sanitaria Locale 3 Genoa, Genoa, Italy, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷University Health Network, Toronto, ON, Canada, ⁸Cleveland Clinic, Cleveland, OH, ⁹Azienda Sanitaria Alto Adige, Brunico, Italy
Background/Purpose: Giant cell arteritis (GCA) is the most common form of large vessel vasculitis. While remission and relapse are common primary endpoints in clinical trials,…
Abstract Number: 1265 • ACR Convergence 2022
External Validation of a Giant Cell Arteritis Probability Score (GCAPS) to Risk Stratify GCA Referrals: Experience from a United Kingdom Fast Track Clinic
Edward Appleby¹ and Qasim Akram², ¹Stockport NHS Foundation Trust, Altrincham, United Kingdom, ²NHS- Stockport, Manchester, United Kingdom
Background/Purpose: Giant Cell Arteritis (GCA) is the most common large vessel vasculitis which can result in irreversible blindness if not diagnosed and treated promptly. We…
Abstract Number: 0472 • ACR Convergence 2022
The Common Carotid Artery in the Ultrasound Evaluation of Giant Cell Arteritis
Charles Oshinsky¹, Alison Bays¹, Ingeborg Sacksen¹, Elizabeth Jernberg², R. Eugene zierler¹ and Scott Pollock¹, ¹University of Washington, Seattle, WA, ²Virginia Mason, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA), the most common large vessel vasculitis, can cause irreversible vision loss if untreated. Vascular ultrasound has been used with greater…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].